FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034409461> ?p ?o ?g. }

• W2034409461 endingPage "67" @default.
• W2034409461 startingPage "67" @default.
• W2034409461 abstract "Brief Reports1 January 1988Metoprolol-lnduced Hepatitis: Rechallenge and Drug Oxidation PhenotypingDOMINIQUE LARREY, M.D., JEAN HENRION, M.D., FRANCIS HELLER, M.D., GERARD BABANY, M.D., CLAUDE DEGOTT, M.D., DOMINIQUE PESSAYRE, M.D., JEAN-PIERRE BENHAMOU, M.D.DOMINIQUE LARREY, M.D.Search for more papers by this author, JEAN HENRION, M.D.Search for more papers by this author, FRANCIS HELLER, M.D.Search for more papers by this author, GERARD BABANY, M.D.Search for more papers by this author, CLAUDE DEGOTT, M.D.Search for more papers by this author, DOMINIQUE PESSAYRE, M.D.Search for more papers by this author, JEAN-PIERRE BENHAMOU, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-108-1-67 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptMetoprolol is a widely used beta-adrenoreceptor antagonist. To our knowledge, there is no report of hepatitis involving this drug as well as other beta-adrenoreceptor antagonists (1). Metoprolol is metabolized by three major oxidation pathways (2); two of them, O-dealkylation and alpha-hydroxylation, undergo genetically controlled polymorphisms correlated with that of debrisoquine oxidation (2-4). This finding strongly suggests that metoprolol oxidation depends at least partly on the same isozyme of cytochrome P-450 involved in the genetic polymorphism of oxidation of debrisoquine and many other drugs such as sparteine, perhexiline, and several other beta-adrenoreceptor antagonists (5). Poor metabolizers of debrisoquine and metoprolol exhibit...References1. STRICKER B and SPOELSTRA P. Drug-Induced Hepatic Injury: A Comprehensive Survey of the Literature on Adverse Drug Reactions up to January 1985. Amsterdam: Elsevier; 1985: 96-7. Google Scholar2. SILAS J, MCGOURTY J, LENNARD M, TUCKER G, and WOODS H. Polymorphic metabolism of metoprolol: clinical studies. Eur J Clin Pharmacol. 1985;28 (suppl):85-8. CrossrefMedlineGoogle Scholar3. LENNARD M, SILAS J, FREESTONE S, RAMSAY L, TUCKER G, and WOODS H. Oxidation phenotype—a major determinant of metoprolol metabolism and response. N Engl J Med. 1982;307:1558-60. CrossrefMedlineGoogle Scholar4. MCGOURTY J, SILAS J, LENNARD M, TUCKER G, and WOODS H. Metoprolol metabolism and debrisoquine oxidation polymorphism—population and family studies. Br J Clin Pharmacol. 1985;20:555-66. CrossrefMedlineGoogle Scholar5. JACQZ E, HALL S, and BRANCH R. Genetically determined polymorphisms in drug oxidation. Hepatology. 1986;6:1020-32. CrossrefMedlineGoogle Scholar6. MORGAN M, RESHEF R, SHAH R, OATES N, SMITH R, and SHERLOCK S. Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut. 1984;25:1057-64. CrossrefMedlineGoogle Scholar7. EVANS D, MAHGOUB A, SLOAN T, IDLE J, and SMITH R. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet. 1980;17:102-5. CrossrefMedlineGoogle Scholar8. SHEAR N, SPIELBERG S, GRANT D, TANG B, and KALOW W. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med. 1986;105:179-84. LinkGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: DOMINIQUE LARREY, M.D.; JEAN HENRION, M.D.; FRANCIS HELLER, M.D.; GERARD BABANY, M.D.; CLAUDE DEGOTT, M.D.; DOMINIQUE PESSAYRE, M.D.; JEAN-PIERRE BENHAMOU, M.D.Affiliations: Hôpital Beaujon Clichy France Hôpital de Jolimont Haine Saint-Paul Belgium PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAcute liver injury induced by drug interaction between dacomitinib and metoprolol due to the inhibition of CYP2D6 by dacomitinibIdentification of Metoprolol Tartrate-Derived Reactive Metabolites Possibly Correlated with Its Cytotoxicityβ-Blocker-Induced Liver Injury: A Class Effect With Incidental RechallengeDrug-Induced Liver InjuryDrug-Induced Liver InjuryLevetiracetam-induced transaminitis in a young male with traumatic brain injuryDrug-induced HepatotoxicityMetoprololHepatotoxicity of Cardiovascular and Antidiabetic DrugsDrug-Induced Liver InjuryDrug‐Induced Liver DiseaseDrug-Induced Liver InjuryLiver Disease Caused by DrugsFatal subacute liver failure after repeated administration of sevoflurane anaesthesiaCiprofloxacin-Induced Hepatotoxicity Resolved with Levofloxacin: A Case Report and a Review of the LiteratureAtenolol Hepatotoxicity: Report of a Complicated CaseClopidogrel-Induced Hepatocellular Injury and Cholestatic Jaundice in an Elderly Patient: Case Report and Review of the LiteratureDrugs Used to Treat Hypertension, Heart Failure, and Angina PectorisMetoprololDrug-Induced Liver InjuryMetoprolol 37350-58-6Fosinopril-induced prolonged cholestatic jaundice and pruritus: first case reportAcute Cholestatic Hepatitis Associated With PravastatinGENETIC PREDISPOSITION TO DRUG-INDUCED LIVER DISEASEHepatotoxityHypersensitivity Immune Reaction as a Mechanism for Dilevalol-Associated HepatitisClinical consequences of polymorphic drug oxidationLabetalol HepatotoxicityJohn A. Clark, MD, MSPH, Hyman J. Zimmerman, MD, Lelia Ann Tanner, RPhFatal labetalol-induced hepatic injuryDrug-induced Liver DiseaseGenetically determined oxidation polymorphism and drug hepatotoxicityβ-Adrenoceptor antagonists and antianginal drugs 1 January 1988Volume 108, Issue 1Page: 67-68KeywordsDrugsGenetic polymorphismHepatitis AHepatitis B ePublished: 1 December 2008 Issue Published: 1 January 1988 PDF downloadLoading ..." @default.
• W2034409461 created "2016-06-24" @default.
• W2034409461 creator A5021514439 @default.
• W2034409461 creator A5033485067 @default.
• W2034409461 creator A5035573552 @default.
• W2034409461 creator A5035641438 @default.
• W2034409461 creator A5038743979 @default.
• W2034409461 creator A5053420000 @default.
• W2034409461 creator A5089546666 @default.
• W2034409461 date "1988-01-01" @default.
• W2034409461 modified "2023-09-27" @default.
• W2034409461 title "Metoprolol-lnduced Hepatitis: Rechallenge and Drug Oxidation Phenotyping" @default.
• W2034409461 cites W2000506686 @default.
• W2034409461 cites W2058391540 @default.
• W2034409461 cites W2071081748 @default.
• W2034409461 cites W2092510009 @default.
• W2034409461 cites W2107472157 @default.
• W2034409461 cites W2153648434 @default.
• W2034409461 cites W2171603185 @default.
• W2034409461 doi "https://doi.org/10.7326/0003-4819-108-1-67" @default.
• W2034409461 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/3337519" @default.
• W2034409461 hasPublicationYear "1988" @default.
• W2034409461 type Work @default.
• W2034409461 sameAs 2034409461 @default.
• W2034409461 citedByCount "35" @default.
• W2034409461 countsByYear W20344094612012 @default.
• W2034409461 countsByYear W20344094612013 @default.
• W2034409461 countsByYear W20344094612014 @default.
• W2034409461 countsByYear W20344094612017 @default.
• W2034409461 countsByYear W20344094612018 @default.
• W2034409461 countsByYear W20344094612019 @default.
• W2034409461 countsByYear W20344094612022 @default.
• W2034409461 crossrefType "journal-article" @default.
• W2034409461 hasAuthorship W2034409461A5021514439 @default.
• W2034409461 hasAuthorship W2034409461A5033485067 @default.
• W2034409461 hasAuthorship W2034409461A5035573552 @default.
• W2034409461 hasAuthorship W2034409461A5035641438 @default.
• W2034409461 hasAuthorship W2034409461A5038743979 @default.
• W2034409461 hasAuthorship W2034409461A5053420000 @default.
• W2034409461 hasAuthorship W2034409461A5089546666 @default.
• W2034409461 hasConcept C109650736 @default.
• W2034409461 hasConcept C126322002 @default.
• W2034409461 hasConcept C2777600422 @default.
• W2034409461 hasConcept C2780035454 @default.
• W2034409461 hasConcept C2781280847 @default.
• W2034409461 hasConcept C33664856 @default.
• W2034409461 hasConcept C526171541 @default.
• W2034409461 hasConcept C62231903 @default.
• W2034409461 hasConcept C71924100 @default.
• W2034409461 hasConcept C89311334 @default.
• W2034409461 hasConcept C98274493 @default.
• W2034409461 hasConceptScore W2034409461C109650736 @default.
• W2034409461 hasConceptScore W2034409461C126322002 @default.
• W2034409461 hasConceptScore W2034409461C2777600422 @default.
• W2034409461 hasConceptScore W2034409461C2780035454 @default.
• W2034409461 hasConceptScore W2034409461C2781280847 @default.
• W2034409461 hasConceptScore W2034409461C33664856 @default.
• W2034409461 hasConceptScore W2034409461C526171541 @default.
• W2034409461 hasConceptScore W2034409461C62231903 @default.
• W2034409461 hasConceptScore W2034409461C71924100 @default.
• W2034409461 hasConceptScore W2034409461C89311334 @default.
• W2034409461 hasConceptScore W2034409461C98274493 @default.
• W2034409461 hasIssue "1" @default.
• W2034409461 hasLocation W20344094611 @default.
• W2034409461 hasLocation W20344094612 @default.
• W2034409461 hasOpenAccess W2034409461 @default.
• W2034409461 hasPrimaryLocation W20344094611 @default.
• W2034409461 hasRelatedWork W1966222553 @default.
• W2034409461 hasRelatedWork W1975683170 @default.
• W2034409461 hasRelatedWork W1980407312 @default.
• W2034409461 hasRelatedWork W2095584836 @default.
• W2034409461 hasRelatedWork W2117301521 @default.
• W2034409461 hasRelatedWork W2126074592 @default.
• W2034409461 hasRelatedWork W2315129507 @default.
• W2034409461 hasRelatedWork W2359517566 @default.
• W2034409461 hasRelatedWork W2364656071 @default.
• W2034409461 hasRelatedWork W2399165565 @default.
• W2034409461 hasVolume "108" @default.
• W2034409461 isParatext "false" @default.
• W2034409461 isRetracted "false" @default.
• W2034409461 magId "2034409461" @default.
• W2034409461 workType "article" @default.